ストックスクリーナーアプリを入手
56.26
0.66%
0.37
アフターアワーズ：
56.46
0.20
+0.36%
前日終値:
$55.89
開ける：
$56.1
24時間の取引高:
2.00M
Relative Volume:
0.65
時価総額：
$5.12B
収益：
$170.10M
当期純損益:
$-239.59M
株価収益率:
-20.09
EPS:
-2.8
ネットキャッシュフロー:
$-191.20M
1週間 パフォーマンス:
+2.55%
1か月 パフォーマンス:
-0.60%
6か月 パフォーマンス:
+29.36%
1年 パフォーマンス:
+22.60%
1日の値動き範囲:
$55.10
$56.49
1週間の範囲:
$51.63
$56.49
52週間の値動き範囲:
$30.04
$71.13
Crispr Therapeutics Ag Stock (CRSP) Company Profile
CRSP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
56.26 | 4.71B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-14 | アップグレード | Evercore ISI | In-line → Outperform |
| 2025-02-12 | アップグレード | TD Cowen | Sell → Hold |
| 2025-02-03 | 開始されました | H.C. Wainwright | Buy |
| 2024-08-06 | 繰り返されました | Needham | Buy |
| 2024-08-02 | 開始されました | Rodman & Renshaw | Buy |
| 2024-06-28 | 再開されました | Guggenheim | Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-11 | ダウングレード | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | 開始されました | Mizuho | Buy |
| 2023-08-17 | アップグレード | Citigroup | Neutral → Buy |
| 2023-05-30 | 開始されました | William Blair | Outperform |
| 2023-04-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2023-03-17 | 開始されました | Bryan Garnier | Buy |
| 2023-03-07 | 開始されました | Robert W. Baird | Neutral |
| 2022-10-11 | 開始されました | Morgan Stanley | Underweight |
| 2022-08-09 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2022-06-23 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-06-17 | 開始されました | BMO Capital Markets | Outperform |
| 2022-04-28 | 開始されました | Credit Suisse | Neutral |
| 2021-12-07 | 開始されました | Cowen | Market Perform |
| 2021-10-19 | 開始されました | SVB Leerink | Outperform |
| 2021-06-14 | アップグレード | Citigroup | Sell → Neutral |
| 2021-04-21 | アップグレード | Jefferies | Hold → Buy |
| 2021-03-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-12-10 | 繰り返されました | Chardan Capital Markets | Buy |
| 2020-12-10 | ダウングレード | Jefferies | Buy → Hold |
| 2020-12-10 | 繰り返されました | Needham | Buy |
| 2020-12-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | 開始されました | BofA Securities | Buy |
| 2020-07-28 | 繰り返されました | Needham | Buy |
| 2020-07-14 | 開始されました | SunTrust | Buy |
| 2020-06-15 | 繰り返されました | Canaccord Genuity | Buy |
| 2020-03-05 | 開始されました | Stifel | Hold |
| 2020-02-03 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-11-19 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | アップグレード | Oppenheimer | Perform → Outperform |
| 2019-08-01 | 開始されました | Jefferies | Buy |
| 2019-07-26 | 開始されました | Canaccord Genuity | Buy |
| 2019-06-10 | 開始されました | ROTH Capital | Buy |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-14 | 開始されました | William Blair | Mkt Perform |
| 2019-01-28 | ダウングレード | Goldman | Buy → Neutral |
| 2019-01-22 | ダウングレード | Citigroup | Neutral → Sell |
すべてを表示
Crispr Therapeutics Ag (CRSP) 最新ニュース
CRISPR Therapeutics (NASDAQ:CRSP) Trading Up 6.8%What's Next? - MarketBeat
CRISPR Therapeutics (CRSP): Revisiting Valuation in Light of New Clinical Data and Expanding Commercial Momentum - Yahoo Finance
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - sharewise.com
CRISPR Therapeutics AG $CRSP Position Raised by Raymond James Financial Inc. - MarketBeat
Bayforest Capital Ltd Acquires Shares of 12,424 CRISPR Therapeutics AG $CRSP - MarketBeat
Trexquant Investment LP Acquires Shares of 38,831 CRISPR Therapeutics AG $CRSP - MarketBeat
Wall Street Analysts See CRISPR Therapeutics (CRSP) as a Buy: Should You Invest? - sharewise.com
CRISPR Therapeutics AG (CRSP)’s Casgevy Expands Global Adoption in 2025 - Yahoo Finance
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade - sharewise.com
CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025 - GlobeNewswire
First-Ever Human CRISPR Heart Disease Trial: CRISPR Therapeutics Reveals Breakthrough Gene Therapy Results - Stock Titan
CRISPR Therapeutics stock pops following disclosure of RFK Jr. investment - MSN
Can CRISPR Therapeutics AG reach all time highs this year2025 Price Momentum & Technical Pattern Recognition Alerts - 뉴스영
CRISPR Therapeutics AG $CRSP Shares Sold by Baker BROS. Advisors LP - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $71.60 Consensus PT from Brokerages - MarketBeat
Is CRISPR Therapeutics AG part of any major indexJuly 2025 Earnings & Low Risk High Win Rate Picks - beatles.ru
H.C. Wainwright Lifts CRISPR Therapeutics’ (CRSP) Price Target on CASGEVy Sales Growth - MSN
Invesco Ltd. Has $951,000 Stock Position in CRISPR Therapeutics AG $CRSP - MarketBeat
Visual trend scoring systems applied to CRISPR Therapeutics AG2025 Trading Recap & Fast Exit and Entry Strategy Plans - Newser
With 79% Ownership in CRISPR Therapeutics AG (NASDAQ:CRSP), Institutional Investors Have a Lot Riding on the Business - 富途牛牛
How sentiment analysis helps forecast CRISPR Therapeutics AG - Newser
Will CRISPR Therapeutics AG stock hit new highs in YEAR2025 Price Momentum & Daily Profit Maximizing Tips - خودرو بانک
Does CRISPR Therapeutics AG have pricing powerJuly 2025 Outlook & Risk Managed Investment Strategies - خودرو بانک
Will CRISPR Therapeutics AG benefit from geopolitical trendsPortfolio Performance Report & High Accuracy Swing Entry Alerts - خودرو بانک
Will CRISPR Therapeutics AG benefit from current market trendsJuly 2025 Macro Moves & Long-Term Growth Plans - خودرو بانک
Is CRISPR Therapeutics AG a speculative investment2025 Bull vs Bear & Free Community Consensus Stock Picks - خودرو بانک
Can machine learning forecast CRISPR Therapeutics AG recovery2025 EndofYear Setup & Safe Capital Investment Plans - Newser
Will earnings trigger a reversal in CRISPR Therapeutics AGJuly 2025 Earnings & Long-Term Safe Return Strategies - Newser
Identifying reversal signals in CRISPR Therapeutics AG2025 Dividend Review & Short-Term High Return Ideas - Newser
How hedge fund analytics apply to CRISPR Therapeutics AG stockPortfolio Performance Summary & Capital Protection Trading Alerts - Newser
Will CRISPR Therapeutics AG stock recover after recent dropQuarterly Profit Summary & Weekly High Conviction Ideas - Newser
Zacks Research Has Optimistic Outlook of CRSP Q1 Earnings - MarketBeat
Will breakout in CRISPR Therapeutics AG lead to full recoveryQuarterly Profit Summary & High Accuracy Swing Trade Signals - Newser
Orbis Allan Gray Ltd Buys 86,813 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Real time pattern detection on CRISPR Therapeutics AG stockJuly 2025 PostEarnings & Reliable Price Breakout Alerts - Newser
Why This Biotech Company Could Be a Growth Stock Powerhouse - The Motley Fool
Bank of America Securities Sticks to Their Buy Rating for Crispr Therapeutics AG (CRSP) - The Globe and Mail
Forecasting CRISPR Therapeutics AG price range with options dataJuly 2025 Pullbacks & Daily Market Momentum Tracking - Newser
CRISPR Therapeutics (CRSP) Down 5.3% Since Last Earnings Report: Can It Rebound? - sharewise.com
Sentiment analysis tools applied to CRISPR Therapeutics AG2025 EndofYear Setup & Weekly Market Pulse Alerts - Newser
Rafferty Asset Management LLC Trims Stock Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat
Detecting support and resistance levels for CRISPR Therapeutics AGJuly 2025 WrapUp & Daily Volume Surge Signals - Newser
Multi asset correlation models including CRISPR Therapeutics AGJuly 2025 Earnings & Low Risk Entry Point Guides - Newser
Crispr Therapeutics Ag (CRSP) 財務データ
収益
当期純利益
現金流量
EPS
0.93%
0.10%
大文字化:
|
ボリューム (24 時間):